Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH Review Process Improvements Detailed In Report

This article was originally published in The Gray Sheet

Executive Summary

OIVD will initiate a computer-based pilot of its "TURBO" 510(k) program in June, keeping the in vitro diagnostic device office on track to launch the optional program in December, according to FDA

You may also be interested in...



Regulatory News In Brief

CDRH's Kessler on public radio: "Stents are fantastic inventions by medical device companies. I just don't think that the public has any clue that this industry is out there. People talk - with all respect to my sister agency - drugs, drugs, drugs and those are wonderful, but there is technology out there that is really working and the medical device field is outstanding," Office of Science & Engineering Laboratories Director Larry Kessler remarked during an Oct. 6 Kojo Nnamdi Show highlighting the CDRH science office. Later, Kessler alluded to fake Prolene surgical mesh manufactured by a company in India. OSEL testing found that although the counterfeiter's attempt at the J&J product did have some sterility problems, it largely worked as intended. Kessler also discussed timing for OSEL research: "We try to start studies that we do that are going to reflect products that come into the agency for approval anywhere from one to as much as five years ahead of time." Kessler added: "We have been doing a lot of work, for example, in laser diagnosis - that is, using light to diagnose conditions. We are trying to really move ahead, and some of these studies take six months to a year, sometimes two" years...

Regulatory News In Brief

CDRH's Kessler on public radio: "Stents are fantastic inventions by medical device companies. I just don't think that the public has any clue that this industry is out there. People talk - with all respect to my sister agency - drugs, drugs, drugs and those are wonderful, but there is technology out there that is really working and the medical device field is outstanding," Office of Science & Engineering Laboratories Director Larry Kessler remarked during an Oct. 6 Kojo Nnamdi Show highlighting the CDRH science office. Later, Kessler alluded to fake Prolene surgical mesh manufactured by a company in India. OSEL testing found that although the counterfeiter's attempt at the J&J product did have some sterility problems, it largely worked as intended. Kessler also discussed timing for OSEL research: "We try to start studies that we do that are going to reflect products that come into the agency for approval anywhere from one to as much as five years ahead of time." Kessler added: "We have been doing a lot of work, for example, in laser diagnosis - that is, using light to diagnose conditions. We are trying to really move ahead, and some of these studies take six months to a year, sometimes two" years...

Global Diagnostics In Brief

Computer-aided detection: Siemens Medical's Mammomat Novation digital mammography system will integrate iCAD's Second Look Digital software as part of a three-year, worldwide licensing and distribution agreement. In a July 8 release, iCAD notes that U.S. product release is slated for 2005, following FDA approval of Mammomat, already cleared internationally. Last month, iCAD announced integration of its film-based analysis tool, Second Look 500M, with Confirma's MRI CAD to aid breast cancer detection....CADstream: Kirkland, Wash.-based Confirma launches CADstream 3.1 next-gen breast MRI analysis device July 8, following 510(k) clearance the previous day. The system includes SureLoc technology, allowing "automatic CAD-analysis and reporting of lesion location and calculations at the point of procedure," Confirma states. Other features include enhanced remote viewing and automatic reading capability within a 2-D region of interest. On July 1, GE Healthcare said it would distribute CADstream software to its global MRI customers...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel